1 BTC
=
- USD
Absci Corporation Common Stock
As of May 31, 2026 at 24:02 UTC
Chart
About Absci Corporation Common Stock
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.
Market Statistics
Trading Metrics
How to Buy ABSI
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy ABSI
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesAMD disclosed a $6.5 million stake in Marvell Technology through its latest 13F filing, with the position showing an estimated unrealized gain of approximately $4.3 million as Marvell shares have risen about 66% from AMD's implied entry price. The investment reflects AMD's exposure to AI infrastructure and data center semiconductor opportunities. AMD also holds positions in Absci Corp, Sanmina Corp, and Xanadu Quantum Technologies.
Absci Corporation granted 276,200 non-statutory stock options to a newly-hired non-executive employee on May 1, 2026, as an inducement for employment. The options have an exercise price of $4.92 per share with a 10-year term and vest over four years, with 25% vesting after one year and the remaining 75% vesting in equal monthly installments over the following three years.
Absci Corporation announced the appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer to lead clinical development of its AI-designed therapeutics pipeline. Dr. Somaratne joins from Vertex Pharmaceuticals with extensive experience in clinical development. Chief Innovation Officer Andreas Busch will retire on March 31, 2026 and transition to co-chair the Scientific Advisory Board.
Absci, a clinical-stage biotech company using generative AI for drug discovery, will report its Q3 2025 financial and operating results on November 12, 2025, via a webcast conference call.
Absci Corporation announced participation in upcoming healthcare investor conferences and plans to host a key opinion leader (KOL) seminar on its ABS-201 hair regrowth program, with an accelerated Phase 1/2a trial expected to begin in December 2025.
